Barh / Lundstrom | COVID-19 | Buch | 978-1-032-04063-9 | sack.de

Buch, Englisch, 238 Seiten, Format (B × H): 183 mm x 260 mm, Gewicht: 654 g

Barh / Lundstrom

COVID-19

From Bench to Bedside
1. Auflage 2022
ISBN: 978-1-032-04063-9
Verlag: CRC Press

From Bench to Bedside

Buch, Englisch, 238 Seiten, Format (B × H): 183 mm x 260 mm, Gewicht: 654 g

ISBN: 978-1-032-04063-9
Verlag: CRC Press


The COVID-19 pandemic has affected the entire world in an unprecedented way, and this book provides an overview of the historical facts as well as ongoing approaches to tackle the COVID-19 pandemic. Experts of the respective domains provide details on anti-SARS-CoV-2 drug strategies, including repurposing drugs used for other indications and the development of novel drugs looking at different approaches to target virus entry and replication. COVID-19 vaccine development based on inactivated and attenuated live virus, protein subunit and peptide-based vaccines and utilization of vaccine candidates based on viral vectors, DNA and RNA are presented for both preclinical studies and clinical trials.

Key Features

- Explains the background of the COVID-19 pandemic, the current progress in the development of treatments and prevention of COVID-19 including future aspects of dealing with the pandemic

- Serves as a timely repository of knowledge on COVID-19 for researchers and medical professionals engaged in its management

Barh / Lundstrom COVID-19 jetzt bestellen!

Zielgruppe


Postgraduate, Professional, and Professional Reference

Weitere Infos & Material


Chapter 1 Coronavirus epidemics and the current COVID-19 pandemic

Chapter 2 Biology of Coronaviruses and Predicted Origin of SARS-CoV-2

Chapter 3 Therapeutic Challenges in COVID-19

Chapter 4 Prevention and Control Strategies for COVID-19 Pandemic

Chapter 5 Global Focus and Interdisciplinary Approaches in COVID-19 Research and Their Outcomes

Chapter 6 The evolution of COVID-19 diagnostics

Chapter 7 Drug repurposing and novel antiviral drugs for COVID-19 management

Chapter 8 Convalescent Plasma and Antibody Therapy in COVID-19

Chapter 9 Application Stem Cell and Exosome Based Therapy in COVID-19

Chapter 10 Host and Pathogen-Specific Drug Targets in COVID-19

Chapter 11 Computational biology and bioinformatics in anti-SARS-CoV-2 drug development

Chapter 12 Nanomaterials in COVID-19 drug development

Chapter 13 Vaccine Development Strategies and the Current Status of COVID-19 Vaccines

Chapter 14 Clinical trials of COVID-19 therapeutics and vaccines: history, current status, and limitations

Chapter 15 Lessons Learned from COVID-19 and Their Implementations for Future Pandemics


Dr. Debmalya Barh is currently a Visiting Full Professor (Titular, Grade-E) at the Department of Genetics, Ecology and Evolution, Institute of Biological Sciences (ICB), Federal University of Minas Gerais (UFMG), Brazil. He is also an honorary Scientist at Institute of Integrative Omics and Applied Biotechnology (IIOAB), India.

Dr. Kenneth Lundstrom is currently the CEO of PanTherapeutics in Lausanne, Switzerland.He serves on editorial boards of various journals including Biomedicines and Viruses, and acts as Editor-in-chief for Frontiers in Translational Virology.



Ihre Fragen, Wünsche oder Anmerkungen
Vorname*
Nachname*
Ihre E-Mail-Adresse*
Kundennr.
Ihre Nachricht*
Lediglich mit * gekennzeichnete Felder sind Pflichtfelder.
Wenn Sie die im Kontaktformular eingegebenen Daten durch Klick auf den nachfolgenden Button übersenden, erklären Sie sich damit einverstanden, dass wir Ihr Angaben für die Beantwortung Ihrer Anfrage verwenden. Selbstverständlich werden Ihre Daten vertraulich behandelt und nicht an Dritte weitergegeben. Sie können der Verwendung Ihrer Daten jederzeit widersprechen. Das Datenhandling bei Sack Fachmedien erklären wir Ihnen in unserer Datenschutzerklärung.